$RLFTF DD (opinion) by Whino on Yh-0: Now that we have the

New Post Public Reply Private Reply Replies (0) Message Board
mc67
715
$RLFTF DD (opinion) by Whino on Yh-0: Now that we have the new 60 day scientific report SSRN,

I am even more confident we get EUA for the IV form. We learned that the adjustments made in the formula to calculate the primary endpoint was PRE-SPECIFIED, BEFORE UNBLINDING the data. This means bias was not introduced, the 'books' were not 'cooked', and the FDA guidelines were followed: "Sponsors should submit a statistical analysis plan for review before any unblinding of data", pg 15. Per the new 60 day SSRN, on pg 6, "Site of care was added as a covariate after recognition prior to unblinding." Again, the adjustments made were PRIOR TO UNBLINDING.

Furthermore, it is extremely common and ENCOURAGED to adjust, before unblinding, per FDA guidance: "To improve the precision of treatment effect estimation and inference, sponsors should consider adjusting for prespecified prognostic baseline covariates (e.g., age, baseline severity, comorbidities, baseline medications and COVID-19 vaccination status) in the primary efficacy analysis and should propose methods of covariate adjustment." The key part is "adjusting for prespecified prognostic baseline covariates".

The following prespecified adjustments were made before unblinding: ventilator use, site, use of Remdesivir, baseline respiratory distress ratio, and body mass index. Why do we adjust? We adjust to IMPROVE the PRECISION of TREATMENT EFFECT; to better measure capability of the drug. As an example, a Ferrari engine in bumper to bumper traffic is the SAME engine capability-wise as on a race track. The capabilities just are not able to be exercised to their full effect due to an external variable: traffic. Adjusting for traffic in order to assess the Ferrari engine true capabilities obviously IMPROVES the PRECISION of EFFECT of measuring the engine (drug) capability.

ICU overload is akin to driving a Ferrari in traffic. Science shows that as ICU load approaches capacity, more people die of Covid. Putting a very sick Covid patient in literally a parking lot bed due to ICU overload results in death, per the SSRN: "However, the COVID surge challenged these sites with 200% higher ICU demand resulting in makeshift patient beds erected in parking lots and other non-traditional sites of care. Bravata and colleagues have shown that as ICU capacity reaches 100%, mortality in treatment of critical Covid-19 doubles. The ICUs in the regional hospitals who participated in this trial were far above 100% capacity" pg 7.

In short, the data is good. Recovery and Survival endpoints have been met, are statistically significant. The biological effect of the drug is real. The drug WORKS. I am confident on EUA.

On Management: Obviously not a good look on this quarrel. It is best to keep this sort of thing in-house, private. I am of the opinion, however, that the issues will be resolved because the Drug will be successful. Winning cures all. As a metaphor, we learned in 'The Last Dance' documentary, the 6-time championship Michael Jordan lead Bulls, was FULL of TURMOIL. Between and amongst the Owner, Coaches, and Players, there were all sorts of issues and fighting. But the Bulls just kept on winning - and therefore the team stayed together. Winning is the cure.

I still content that Lavin and Javitt are masters at their craft - at the science and getting FDA approvals. It would be great if JJ was also a smooth operator CEO, but there clearly have been some mishaps. But smooth talking CEO's are a dime a dozen. Much more rare, and valuable, is the ability of the management team to execute on FDA approvals (or EUAs). if I had to choose between a smooth operator and execution with FDA, I'll choose the latter everytime!

Read More: https://investorshangout.com/post/view?id=611...z6scJWPyDE
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Coca-Cola's Emerging Markets Strategy Fuels Long-Term Growth

Updated Category News Views 929

Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...

Continue Reading
Voda IQ Appoints Armando Piccinini to Drive European Sales

Updated Category News Views 121

Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...

Continue Reading
Magnera Corporation to Shine at Upcoming Finance Conference

Updated Category News Views 163

Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...

Continue Reading
Bullish Momentum Unveiled: Insights on Merck & Co Stocks

Updated Category News Views 180

Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...

Continue Reading
Gilead Snags Arcellx: A High-Stakes Cancer Gamble Unfolds

Updated Category News Views 195

The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...

Continue Reading